StreetAlpha.app
Home › Stocks › LEGN

Legend Biotech Corp (LEGN)

Healthcare
$16.11
▲ +0.75%
LAST CLOSE · NOV 17

Legend Biotech develops and sells cell therapies for cancer, led by CARVYKTI for multiple myeloma. It last closed at $16.11 on Nov 17, up 0.75% on the day. LEGN last reported earnings on Tue, Nov 10, 2026. The average 12-month price target from 6 analysts is $38.67 (+140.0% from the last close), with a high of $61.00 and a low of $20.00. Analyst consensus is Buy, based on the latest ratings from 6 firms (4 buy, 2 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in LEGN, 0% of them bullish and 100% bearish. In the past 30 days there were 4 dark pool prints totaling $8.3M, the largest $6.2M.

AI Auto Pilots
Is LEGN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$1.0B
+64.0% vs a year ago
Net income
−$296.8M
−28.8% margin
Free cash flow
−$128.8M
−12.5% margin
Operating margin
−13.3%
−$136.5M operating income
Balance sheet
Cash & equivalents
$901.9M
At Dec 31
Debt
$319.1M
At Dec 31
Shareholder equity
$1.0B
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $68.8M$68.8MFY2021FY2022: $50.3M$50.3MFY2022FY2023: $285.1M$285.1MFY2023FY2024: $627.3M$627.3MFY2024FY2025: $1.0B$1.0BFY2025

From LEGN's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 10). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.

Last report
Nov 10
2026 · Before the open (BMO)
Reported EPS
$0.28
vs $0.01 est. · beat
Year-ago EPS
—
Not on file
Options-implied move
±8.4%
Priced in before that report
Analyst consensus
Buy
Based on 6 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Buy
6firms
4 Buy2 Hold0 Sell
Each firm's latest rating on LEGN in the past 90 days
Average 12-month target
$38.67
▲ 140.0% upside

Based on 6 analysts who set a price target on LEGN in the past 90 days. The average target is $38.67, with a high of $61.00 and a low of $20.00, compared with the last close of $16.11.

Low $20.00Avg $38.67High $61.00
Blue marker: last close $16.11
Highest target$61.00
Average target$38.67
Lowest target$20.00
Latest rating changes
Evercore ISI GroupDowngrade
Nov 16Hold$20
OppenheimerMaintained
Nov 11Buy$25
Morgan StanleyMaintained
Nov 11Buy$43
BarclaysTarget lowered
Nov 11Buy$68 → $61
RBC CapitalTarget lowered
Nov 11Buy$56 → $50
DateFirmActionRatingPrice target
Nov 16Evercore ISI GroupDowngradeHold$20
Nov 11OppenheimerMaintainedBuy$25
Nov 11Morgan StanleyMaintainedBuy$43
Nov 11BarclaysTarget loweredBuy$68 → $61
Nov 11RBC CapitalTarget loweredBuy$56 → $50
Loading…

Technical Analysis

LEGN · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 27% below its 20 day and 20% below its 50 day average. It is 38% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 34), oversold. The nearest support is the 52 week low at $15.75, and the nearest resistance the Pivot at $16.12.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 8.8%/day
Key levels
$37.5052 week high+132.8%
$22.18200 day average+37.7%
$20.95100 day average+30.0%
$20.4420 day average+26.9%
$19.92Swing high (Oct 15)+23.6%
$19.3750 day average+20.2%
$16.49Pivot R1+2.4%
$16.12Pivot+0.1%
$16.11Last close
$15.7552 week low−2.2%
$15.74Pivot S1−2.3%
Indicators
RSI (14)33.83Weak, oversold below 30Neutral
MACD-0.57Below its signal lineBearish
Stochastic2.0Near the bottom of its rangeOversold
ADX (14)23.5Weak trend
Williams %R-95.8Oversold below −80, overbought above −20Oversold
CCI (20)-153.8Oversold below −100, overbought above 100Oversold
Rate of change−25.0%Change over 10 sessionsBearish
ATR (14)$1.41Typical daily range, 8.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for LEGN

What happened before

See how LEGN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow LEGN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How LEGN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
0
0%
Bearish
1
100%
Date span
Sep 24 – Sep 24
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
4
Notional
$8.3M
Largest print
$6.2M
Loading…

LEGN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲119 buying vs 101 selling
  • ▼Shares held by funds -4.3%
  • ▼Funds holding -23
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding197220−10.5%
In funds' top 101112−8.3%
Held by funds–––
New / increased33 / 8656 / 61+1.7%
Reduced / sold out47 / 5477 / 27−2.9%
Put/call ratio2.301.00+130.3%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See LEGN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LEGN is in one of them and how their past LEGN trades turned out.

LEGN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered LEGN in an article yet. Here's the latest on the wider market.

About Legend Biotech

Legend Biotech is a biopharmaceutical company in Somerset, New Jersey, that discovers, develops, manufactures and commercializes cell therapies for cancer. Its main product, CARVYKTI, treats multiple myeloma, a blood cancer, and is made from each patient's own immune cells. The company develops this therapy with Janssen and has other cancer cell therapies in early development, including for lung, gastric and pancreatic cancer.

Headquarters
Somerset, NJ